Workflow
宝鼎科技(002552) - 2025 Q2 - 季度业绩预告

Expected Performance for the Current Period The company anticipates a significant year-over-year decline in its 2025 first-half net profit attributable to shareholders Performance Forecast Summary | Item | Current Reporting Period (Jan 1 - Jun 30, 2025) | Prior Year Period | | :--- | :--- | :--- | | Net Profit Attributable to Shareholders | Profit: 18.00 million - 26.00 million yuan | Profit: 101.262 million yuan | | Year-over-Year Change | Decrease: 74.32% - 82.22% | - | | Net Profit Excluding Non-Recurring Gains/Losses | Profit: 20.00 million - 28.00 million yuan | Profit: 31.5754 million yuan | | Year-over-Year Change | Decrease: 11.32% - 36.66% | - | | Basic Earnings Per Share | Profit: 0.04 - 0.06 yuan/share | Profit: 0.24 yuan/share | Communication with Accounting Firm The company clarifies that the performance forecast data is a preliminary internal estimate, pending audit by its annual accounting firm - The performance forecast data has not been audited by the company's annual accounting firm4 Explanation of Performance Changes Net profit decline is attributed to a high comparative base from prior-year non-recurring gains and core business downturn - The primary reason for the performance decline is a high comparative base, due to 84.6581 million yuan in investment income from the sale of Baoding Heavy Industry and Baoding Scrap Metal equity in the prior year period5 - Core business segments, specifically copper clad laminate and copper foil, experienced decreased sales volume, leading to lower operating revenue and gross margins, negatively impacting current period profit5 Risk Warning and Other Related Information The company warns this performance forecast is preliminary, with final data in the 2025 semi-annual report - This performance forecast is a preliminary estimate, and the final financial data will be subject to the company's 2025 semi-annual report disclosure6 - The company advises investors to exercise caution in their decisions and be aware of investment risks6